New bladder cancer cocktail aims to save the bladder
NCT ID NCT05975307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a combination of chemotherapy, an immunotherapy drug called toripalimab, and radiation can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. About 71 adults with this type of bladder cancer will receive the drugs first, then those who respond well will get radiation plus more immunotherapy. The main goal is to see if the cancer disappears completely after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with chemotherapy (gemcitabine and cisplatin/carboplatin) and radiotherapy
What this could lead to
If successful, this could offer a bladder-sparing treatment option for muscle-invasive bladder cancer, avoiding the need for surgical removal of the bladder.
What could go wrong
This is a small, early-phase trial with only 71 participants, so results may not apply to everyone. Combining immunotherapy with chemotherapy and radiation can cause significant side effects, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China